Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

A multi-centre phase 3 study comparing efficacy and safety of Bemfola(®) versus Gonal-f(®) in women undergoing ovarian stimulation for IVF

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Meditation and mindfulness reduce perceived stress in women with recurrent pregnancy loss: a randomized controlled trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Stress and depression among women and men who have experienced recurrent pregnancy loss: focusing on both sexes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Empathetic application of machine learning may address appropriate utilization of ART

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Futures and fears in the freezer: Danish women's experiences with ovarian tissue cryopreservation and transplantation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. The reproductive microbiome - clinical practice recommendations for fertility specialists

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  • M Rettenbacher
  • A N Andersen
  • J A Garcia-Velasco
  • M Sator
  • P Barri
  • S Lindenberg
  • K van der Ven
  • Y Khalaf
  • U Bentin-Ley
  • A Obruca
  • G Tews
  • M Schenk
  • T Strowitzki
  • N Narvekar
  • K Sator
  • B Imthurn
Vis graf over relationer

Bemfola (follitropin alfa) (Finox AG, Switzerland), a new recombinant FSH, has a comparable pharmacological profile to that of Gonal-f (Merck Serono, Germany), the current standard for ovarian stimulation. A randomized, multi-centre, Phase 3 study in women undergoing IVF or intracytoplasmic sperm injection (n = 372) showed Bemfola yielding similar efficacy and safety profiles to Gonal-f. Women aged 20-38 years of age were randomized 2:1 to receive a single, daily, subcutaneous 150 IU dose of either Bemfola or Gonal-f. This study tested equivalence in the number of retrieved oocytes using a pre-determined clinical equivalence margin of ±2.9 oocytes. Compared with Gonal-f, Bemfola treatment resulted in a statistically equivalent number of retrieved oocytes (Bemfola 10.8 ± 5.11 versus Gonal-f 10.6 ± 6.06, mean difference: 0.27 oocytes, 95% confidence interval: -1.34, 1.32) as well as a similar clinical pregnancy rate per embryo transfer in first and second cycles (Bemfola: 40.2% and 38.5%, respectively; Gonal-f: 48.2% and 27.8%, respectively). No difference in severe ovarian hyperstimulation syndrome was observed between treatment groups (Bemfola: 0.8%; Gonal-f: 0.8%). This study demonstrates similar clinical efficacy and safety profiles between Bemfola and Gonal-f, and suggests that Bemfola can be an appropriate alternative in ovarian stimulation protocols.

TidsskriftReproductive BioMedicine Online
Udgave nummer5
Sider (fra-til)504-13
Antal sider10
StatusUdgivet - maj 2015

ID: 46175828